Cheryl Grise - MetLife Lead Independent Director
MET Stock | USD 86.51 0.49 0.56% |
Director
Ms. Cheryl W. Grise, J.D., is an Independent Director of MetLife, Inc since 2017.
Age | 67 |
Tenure | 8 years |
Address | 200 Park Avenue, New York, NY, United States, 10166-0188 |
Phone | 212 578 9500 |
Web | https://www.metlife.com |
Cheryl Grise Latest Insider Activity
Tracking and analyzing the buying and selling activities of Cheryl Grise against MetLife stock is an integral part of due diligence when investing in MetLife. Cheryl Grise insider activity provides valuable insight into whether MetLife is net buyers or sellers over its current business cycle. Note, MetLife insiders must abide by specific rules, including filing SEC forms every time they buy or sell MetLife'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Cheryl Grise over six months ago Acquisition by Cheryl Grise of 627 shares of MetLife at 69.86 subject to Rule 16b-3 | ||
Cheryl Grise over six months ago Acquisition by Cheryl Grise of 623 shares of MetLife at 69.06 subject to Rule 16b-3 |
MetLife Management Efficiency
Return On Equity is likely to gain to 0.09 in 2025, whereas Return On Tangible Assets are likely to drop 0 in 2025. At this time, MetLife's Non Current Liabilities Total is comparatively stable compared to the past year. Change To Liabilities is likely to gain to about 5.4 B in 2025, whereas Total Current Liabilities is likely to drop slightly above 431.8 M in 2025. MetLife's management efficiency ratios could be used to measure how well MetLife manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | DIRECTOR Age | ||
Gary Kelly | Lincoln National | 65 | |
Karole Lloyd | Aflac Incorporated | 62 | |
Ming Lu | Prudential PLC ADR | 62 | |
Toshihiko Fukuzawa | Aflac Incorporated | 63 | |
Philip Remnant | Prudential PLC ADR | 66 | |
Kaikhushru Nargolwala | Prudential PLC ADR | 69 | |
Thomas Watjen | Prudential PLC ADR | 66 | |
Michael Mee | Lincoln National | 77 | |
David Law | Prudential PLC ADR | 60 | |
Jeremy Anderson | Prudential PLC ADR | 63 | |
Gilbert Casellas | Prudential Financial | 68 | |
Reginald Davis | Lincoln National | 57 | |
Deirdre Connelly | Lincoln National | 59 | |
Susan Cross | Unum Group | 60 | |
Thomas Kenny | Aflac Incorporated | 57 | |
Susan DeVore | Unum Group | 62 | |
Martina HundMejean | Prudential Financial | 60 | |
George Paz | Prudential Financial | 65 | |
Theodore Bunting | Unum Group | 62 | |
George Sartorel | Prudential PLC ADR | 63 | |
Ronald Hanley | Unum Group | 63 |
Management Performance
Return On Equity | 0.13 | ||||
Return On Asset | 0.0058 |
MetLife Leadership Team
Elected by the shareholders, the MetLife's board of directors comprises two types of representatives: MetLife inside directors who are chosen from within the company, and outside directors, selected externally and held independent of MetLife. The board's role is to monitor MetLife's management team and ensure that shareholders' interests are well served. MetLife's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, MetLife's outside directors are responsible for providing unbiased perspectives on the board's policies.
MBA BS, Chief VP | ||
Catherine Kinney, Independent Director | ||
Randolph Clerihue, Chief Officer | ||
Carlos Gutierrez, Independent Director | ||
Michael Roberts, Executive Vice President Chief Marketing Officer | ||
Pawan Verma, Executive Vice President, Chief Information Officer | ||
Stephen Gauster, Senior Vice President Interim General Counsel | ||
Ramy Tadros, Executive Vice President and President - U.S. Business | ||
Michel Khalaf, President, Chief Executive Officer, Director | ||
Shurawl Sibblies, Executive Officer | ||
Bill Pappas, Executive Vice President Head of Global Technology and Operations | ||
Diana McKenzie, Independent Director | ||
Randy Stram, Senior Benefits | ||
Cheryl Grise, Lead Independent Director | ||
Susan MBA, Executive Officer | ||
John Hall, Senior Relations | ||
Robert Hubbard, Independent Chairman of the Board | ||
William Kennard, Independent Director | ||
Steven Goulart, Executive Vice President, Chief Investment Officer | ||
Susan Podlogar, Chief Human Resource Officer, Executive Vice President | ||
Robert Merck, Global MD | ||
David Herzog, Independent Director | ||
Cindy Pace, Global Chief Diversity and Inclusion Officer | ||
Robin Gordon, Chief Data and Analytics Officer | ||
William Moore, President Business | ||
Esther Lee, Executive Vice President Global Chief Marketing Officer | ||
Edward Kelly, Independent Director | ||
Gerald Hassell, Independent Director | ||
Oscar Schmidt, President of Latin America | ||
Michael Farrell, Head EVP | ||
Denise Morrison, Independent Director | ||
Nuria Garcia, Head of EMEA | ||
Monica Curtis, Executive Officer | ||
Marlene Debel, Executive Vice President, Chief Risk Officer | ||
Mark Weinberger, Independent Director | ||
John McCallion, Chief Financial Officer, Executive Vice President | ||
Kishore Ponnavolu, President - Asia Region | ||
John CPA, Executive CFO |
MetLife Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is MetLife a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.13 | ||||
Return On Asset | 0.0058 | ||||
Profit Margin | 0.05 % | ||||
Operating Margin | 0.15 % | ||||
Current Valuation | 74.11 B | ||||
Shares Outstanding | 692.42 M | ||||
Shares Owned By Insiders | 16.41 % | ||||
Shares Owned By Institutions | 75.94 % | ||||
Number Of Shares Shorted | 7.4 M | ||||
Price To Earning | 28.61 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for MetLife Stock Analysis
When running MetLife's price analysis, check to measure MetLife's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MetLife is operating at the current time. Most of MetLife's value examination focuses on studying past and present price action to predict the probability of MetLife's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MetLife's price. Additionally, you may evaluate how the addition of MetLife to your portfolios can decrease your overall portfolio volatility.